You searched for "intravitreal"

465 results found

Moorfields Education: Implementing a non-medical intravitreal injection service (Sept 24)

This popular course now comes with funding for NHS Nurses and Allied Health Professionals (AHPs) working within an NHS England Trust which will cover the course attendance fee and also an amount towards necessary travel and accommodation (conditions apply).

A comparative treatment study of VCZ and liposomal AmpB in an Aspergillus fumigatus endophthalmitis model

This study aims to compare the effects of voriconazole (VCZ) and liposomal amphotericin B (AmpB) in an experimental model of exogenous Aspergillus fumigatus endophthalmitis in a guinea pig animal model. Endophthalmitis was induced by intravitreal injection of a strain of...

Lucentis for pseudophakic CMO

Pseudophakic cystoid macular oedema (CMO) develops angiographically in up to 20-30% after uneventful phacoemulsification. This study aimed to evaluate the potential efficacy and safety of intravitreal ranibizumab in patients with pseudophakic CMO after cataract surgery. Seven eyes were included in...

Two-year results of a T&E aflibercept regime in caucasian PNV

This a retrospective study examining two-year outcomes of patients with pachychoroid neovasculopathy (PNV) treated with a treat and extend (T&E) regimen of intravitreal aflibercept. The mean age was 63.84 ± 7.92 years with nine males (35%) and 17 females (65%)....

Subfoveal choroidal thickness and PCV

This report studies the prognostic factors for visual improvement and the need for additional treatments at one year after the initial combination therapy of intravitreal ranibizumab injection or intravitreal aflibercept injection followed by PDT in eyes with PCV. Fifty-six eyes...

Combined ranibizumab and ablative therapy for Coat’s disease

The aim of this study was to observe the efficacy of intravitreal ranibizumab (IVR) combined with laser photocoagulation or cryotherapy, for Coats’ disease. Patients younger than 16 years of age who were diagnosed with Coats’ disease were included in this...

Features of AMD treatment non-responders

This is a retrospective consecutive case series of 365 eyes with age-related macular degeneration (AMD) who had three monthly intravitreal aflibercept treatments for at least 12 months. Responders were defined as complete resolution of exudation, intraretinal oedema, subretinal fluid, pigment...

Aflibercept for the treatment of neovascular glaucoma

The aim of this study was to investigate initial results regarding the treatment of neovascular glaucoma (NVG) with intravitreal aflibercept. NVG is classified into stages 0-3. In stages 1 and 2, abnormal vessel proliferation is seen with or without elevated...

VEGF and axial length (RVU)

The authors of this paper set out to examine whether the concentrations of VEGF in the vitreous were associated with refractive error and axial length in eyes without retinal disease, except of macular holes or epiretinal membranes. A vitreous sample...

Managing cataract surgery in a patient with diabetic maculopathy

A 56-year-old type 2 diabetic with previously treated bilateral diabetic maculopathy develops a cataract requiring surgery in the right eye. He has had grid laser previously, followed intermittently by intravitreal triamcinalone, Avastin and more recently Lucentis in both eyes. His...

Management of diabetic macular oedema in vitrectomised eyes

Diabetic macular oedema (DMO) is one of the leading causes of blindness; its prevalence is on the rise with progressive increase in numbers of people suffering from diabetes. The management of DMO has evolved significantly over the past few years....